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Abstract 
The greatest risk factor for Alzheimer's disease (AD) is advanced age, but the reason for this 
association remains unclear. Amyloid-beta (Aβ) is produced from amyloid precursor protein (APP) 
primarily after APP is internalised by clathrin-mediated or clathrin-independent endocytosis. 
Changes in endocytosis in AD have been identified. We hypothesised that endocytic protein 
expression is altered during ageing, thus influencing the likelihood of developing AD by increasing 
A production. We explored how levels of endocytic proteins, APP, its metabolites, secretase 
enzymes and tau varied with age in cortical brain samples from men of three age ranges (young (20-
30), middle-aged (45-55) and old (70-90)) with no symptoms of dementia. Aβ40 and Aβ42 were 
significantly increased in old brains, while APP and secretase expression was unaffected by age. 
Phosphorylated GSK3β increased significantly with age, a possible precursor for neurofibrillary 
tangle production, although phosphorylated tau was undetectable. Significant increases in clathrin, 
dynamin-1, AP180, Rab-5, caveolin-2 and flotillin-2 were seen in old brains. Rab-5 also increased in 
middle-aged brains prior to changes in Aβ levels. This age-related increase in endocytic protein 
expression, not described previously, suggests an age-related up-regulation of endocytosis which 
could predispose older individuals to develop AD by increasing APP internalisation and Aβ 
generation.  
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Introduction 
Alzheimer's disease (AD) is the most common form of dementia accounting for an estimated 60-80% 
of all cases (1). The brain pathology of AD is characterised by two hallmarks; extracellular senile 
plaques made of amyloid-beta (Aβ) and intracellular neurofibrillary tangles (NFTs) composed of 
hyper-phosphorylated tau (2). Aβ is produced in the amyloidogenic pathway where amyloid precursor 
protein (APP) is cleaved by β-secretase APP-cleaving enzyme (BACE1) to liberate soluble APPβ 
(sAPPβ) and the intracellular β-carboxy-terminal fragment (βCTF) (2). γ-Secretase then cleaves 
βCTF to produce Aβ and a C-terminal fragment (2-3), primarily after APP has undergone endocytosis 
(4). In the non-amyloidogenic pathway α-secretase cleaves APP within Aβ to release soluble APP 
(sAPPα) therefore precluding the production of Aβ (5 ).  
A variety of Aβ peptides exist with Aβ40 and Aβ42 the most abundant isoforms (6). Aβ40 is more 
soluble and found in high levels in both healthy and AD brains, whereas Aβ42 is more hydrophobic, 
considered more toxic and found at significantly higher levels in AD brains (6). Tau, a microtubule-
associated protein essential for protein transport, becomes hyper-phosphorylated in AD due to the 
activity of a number of kinases including glycogen synthase kinase3β (GSK3β) (7).  
One of the earliest reported abnormalities in AD is a change in endocytic processes (8). Cells use a 
variety of highly complex endocytic pathways to internalise material but it is generally considered 
that most cargos enter cells via clathrin-mediated endocytosis (CME) (9). Thus we have concentrated 
on this pathway and two others considered important in the CNS that may be linked to AD; clathrin-
independent endocytosis (CIE) via caveolae or flotillins (8, 10). During CME, plasma membrane 
proteins are packaged into clathrin-coated vesicles which are internalised into the cell and fuse with 
early/sorting endosomes. Material may then be delivered to a variety of compartments including the 
trans-Golgi network (TGN), the lysosomes or recycled back to the plasma membrane ( 11). Besides 
clathrin, CME involves a number of proteins including the scission protein dynamin, adaptor or 
assembly proteins (phosphatidylinositol binding clathrin assembly protein (PICALM), adaptor 
protein complex 2 (AP-2), bridging integrator-1 (BIN-1) and clathrin coat assembly protein (AP180)) 
(11-12). Caveolae are invaginations of the plasma membrane, located in ordered lipid raft domains 
(13) and enriched with caveolin-1, -2 or -3 (11, 14). Once internalised, their contents may interact 
with early and late endosomes (15). Another route for CIE occurs through the lipid raft-associated 
proteins, flotillin-1 and -2 which form non-caveolar microdomains highly expressed in neurones (16-
17).  
Both CME and CIE have been implicated in the process of Aβ generation (18-19). A number of genes 
of small risk for AD were identified in genome-wide association studies (GWAS), including genes 
coding for proteins involved in endocytosis, PICALM, BIN-1 and sorLA (sorting protein-related 
receptor) (20). In addition, early endocytic changes such as enlarged Rab5-positive endosomes and 
increased volume of total endosomes were reported in AD brains (21-22). Furthermore, we have 
shown that the levels of several CME proteins including clathrin, dynamin-2 and PICALM were 
significantly higher in aged 22-month transgenic Tg2576 mice expressing the Swedish mutation of 
human APP compared to age-matched wild-type mice (23). Functionally, inhibition of CME by a 
dynamin dominant-negative inhibitory peptide resulted in lowered brain interstitial Aβ levels (24). 
Changes in the CIE pathway are also implicated in AD since levels of caveolin-1 in the hippocampus 
and cortex were elevated two-fold in AD brains compared to controls (10). In contrast, decreased 
expression of sorLA, associated with APP recycling and normally linked with controlling Aβ levels, 
was found in neurons in AD (25). 
It is well established that ageing is the major risk factor for AD. Approximately 11% of people over 
65 have the disease and this rises to 32% over the age of 85 (1), but the reason for this association 
remains to be elucidated (26). Since changes in A levels in AD patients are known to start 10-15 
years before symptoms associated with memory problems appear (27), it is highly likely that the 
ageing process affects the expression of proteins associated with endocytosis as this is so closely 
linked to the production of Aβ. We therefore hypothesised that the expression of endocytic proteins 
is altered during ageing predisposing older individuals to develop AD. We have investigated this 
hypothesis using brain samples from young, middle-aged and old men with no known history of 
dementia to examine the expression of a range of endocytic proteins involved in CME and CIE, APP 
metabolites and tau. Our data provide evidence for the first time of wide-ranging changes in several 
endocytic proteins with increasing age, suggesting that our hypothesis is indeed correct and that 
alterations in endocytic processes with age could underlie the development of AD. 
Materials and methods 
All chemicals and reagents were purchased from Sigma–Aldrich (Poole, UK) or Fisher Scientific 
(Leicester, UK) unless specified. Antibodies used in Western blotting were: anti N-APP, 22C11 and 
anti-GSK-3α/β (Millipore, Watford, UK); anti-clathrin heavy chain (CHC), Clone 23, anti-caveolin-
2, Clone  65, anti-flotillin-1, Clone  18 and anti-dynamin-2 (BD Biosciences, Oxford, UK); anti-
BACE1 (Merck Chemicals Ltd. Nottingham, UK); anti-AP180 (LP2D11), anti-PICALM, anti-
flotillin-2 and anti-AP-2 (Novus Biologicals, Littleton, CO, USA); anti-caveolin-1 (Cell Signalling 
Technology, Beverly, MA, USA); anti-caveolin-3, anti-presenilin-1 (PS-1), anti-Disintegrin and 
Metalloproteinase domain-containing protein 10, (ADAM10), anti-sorLA (EPR14670), anti-
dynamin-1 and anti-BIN-1 (Abcam, Cambridge, MA); anti-Rab5, S-19 (Santa Cruz Biotechnology, 
SantaCruz, CA, USA) and total tau (Dako, Hamburg, Germany). Monoclonal anti-phospho-tau 
Ser396/Ser404 (PHF-1) was a generous gift from Prof. Peter Davies, Albert Einstein College of 
Medicine, Bronx, NY, USA.  
Human brain samples 
Fresh frozen human frontal cortex brain samples from subjects with no recorded history of dementia 
were obtained from the Sudden Death Edinburgh Brain and Tissue Bank and the Newcastle Brain 
Tissue Resource (Table 1). None of the subjects presented with any neuropathological findings after 
death indicative of AD and the individuals died from the following causes: suicide, fatal overdoses 
of drugs or alcohol, road traffic accidents, various types of cardiovascular disease, cancer and 1 of an 
unknown cause. All subjects were male of three different age ranges; young 20-30, middle-aged 45-
55 and old 70-90 and the mean age ± SD for each group was 26.4 ± 2 years, 49.7 ± 2.2 years and 75.1 
± 4.9 years. The mean post-mortem interval was 57.2 ± 3.5 hours for all samples (Table 1). All 
samples were stored at -80oC prior to use. All procedures were performed in accordance with the 
U.K. Human Tissue Act (2004). 
Tissue processing 
Soluble and insoluble proteins were extracted from cortex samples to allow quantification of Aβ40 
and Aβ42 from each fraction. All other proteins were investigated in the soluble fraction. Proteins 
were extracted using 2% sodium dodecyl sulphate with protease inhibitor cocktail III (Roche) adapted 
from Rees et al. (23,28). Total protein concentration was determined with the BCA Protein Assay Kit 
(Thermo Scientific, Waltham, USA). 
Western Blotting 
Western blotting was performed using standard methods. Briefly, samples were resolved on 7.5-10% 
polyacrylamide gels, transferred on to 0.45µm nitrocellulose membranes (Amersham Biosciences, 
Little Chalfont, U.K.), incubated with the relevant primary antibody and detected as previously 
described (23, 29). 
Quantification of APP, Aβ, βCTF, sAPPα and sAPPβ 
ELISA quantification was performed to detect APP (APP DuoSet ELISA, R&D Systems, Abingdon, 
Oxon., UK), Aβ40, Aβ42, βCTF, sAPPα and sAPPβ (IBL International GmbH, Hamburg, Germany) 
according to the suppliers’ guidelines and as described previously (23, 29-30). Data were presented 
for Aβ as pg/mg total protein concentration, APP, sAPPα and sAPPβ as ng/mg total protein 
concentration and βCTF as pmol/mg total protein concentration. 
APOE genotyping 
Brain tissue DNA extractions were performed using DNeasy blood and tissue kit (Qiagen, Valencia, 
CA, USA). DNA samples were quantified using a Nanodrop spectrophotometer and normalised to a 
concentration of 5ng/µl prior to genotyping. APOE genotypes were determined by TaqMan 
genotyping of single nucleotide polymorphism (SNP) rs7412 and KASP genotyping of SNP rs429358 
as previously described (31). 
Statistical Analysis 
ELISA data were quantified using standard curves with Graphpad Prism5 and normalised to total 
protein concentrations. Western blots were quantified using ImageJ (www.imagej.nih.gov). The 
expression of proteins within each age group were analysed across more than one Western blot. All 
protein bands were expressed as the relative density of the same first human brain sample and 
normalised for GAPDH levels. ELISA results and Western blot data were analysed using one-way 
analysis of variance (ANOVA) followed by Tukey's post-hoc test or Kruskal-Wallis followed by 
Dunn’s post-hoc test to determine whether protein levels differed significantly between young, 
middle-aged or old groups. Data are presented as mean ± SEM. p values < 0.05 were considered 
significant. Where necessary, data were transformed to fit the assumptions of normality and equal 
variances. 
 
Results 
APP metabolites and their inter-relations are altered by ageing 
APP was measured by ELISA (Figure 1A) and Western blot (Supplementary Figure 1A,B) and its 
levels were not affected by age. 
Levels of both soluble and insoluble Aβ40 were very low in young and middle-aged brain samples, 
while a significant increase was detected in old brains compared to the younger two ages (p< 0.05, 
Figure 1B). Soluble Aβ42 was below the detection limits of the ELISA in young and middle-aged 
brains, but was significantly increased in old brains compared to the other ages (p < 0.05, Figure 1C). 
The level of insoluble Aβ42 was very low in young and middle-aged brains, but a large, significant 
increase was seen in old subjects compared to younger men (p< 0.05, Figure 1C). The soluble 
Aβ42/Aβ40 ratio appeared to increase with ageing but was not statistically significant due to the large 
variation in the old subjects (Figure 1D). The insoluble Aβ42/Aβ40 ratio was significantly higher in 
old subjects compared to the younger cases (p< 0.05, Figure 1D). 
βCTF levels were not significantly increased by ageing (Figure 1E). However, there was a weak 
positive correlation between the levels of βCTF and those of soluble/insoluble Aβ40 and soluble 
Aβ42 at certain ages (Supplementary Figure 2A-I), but this correlation was more pronounced with 
insoluble Aβ42 at all ages (r2 = 0.71, p< 0.05 for young samples, Figure 2A, r2 = 0.70, p< 0.05 for 
middle-aged samples, Figure 2B and r2 = 0.98, p< 0.001 for old samples, Figure 2C). While the 
absolute levels of sAPPα and sAPPβ did not change with age (Supplementary Figure 2J,K), their 
inter-relation did. In the young brains, levels of sAPPα were strongly, significantly correlated with 
those of sAPPβ (r2 = 0.82, p< 0.001, Figure 2D) but there was no correlation between sAPPα and 
sAPPβ in middle-aged or old subjects (r2 = 0.011, p> 0.05 for middle-aged, Figure 2E and r2 = 0.006, 
p> 0.05 for old, Figure 2F). 
Since the secretases are essential enzymes for APP processing and Aβ production, we investigated 
whether their expression was altered with ageing. The expression of all three secretases, ADAM10 a 
main α-secretase candidate (5), BACE1 (mature or immature) (32) and presenilin-1 (PS-1, 
representative of γ–secretase) (3) was not affected by age (Supplementary Figure 1A,B).  
Levels of phosphorylated-GSK-3β are increased but total tau is not altered with ageing 
The other main pathology of AD, tau phosphorylation, was also studied and the expression of total 
tau was detected at approximately 45-60 kDa due to multiple tau isoforms (Figure 3A). Tau 
expression was not quantified due to the multiple number of bands, however, the level of total tau 
was clearly not altered with age (Figure 3A). The expression of phosphorylated tau was examined 
using the widely recognised PHF-1 antibody (pSer396/pSer404) (33) but no phosphorylated tau was 
detected in our brain samples even in old individuals (data not shown). We also examined how the 
expression of GSK-3α and GSK-3β may change with ageing as it is one of the most important 
enzymes involved in the phosphorylation of tau. Total GSK-3α and GSK-3β were detected at 49.1 ± 
0.4 kDa and 45.1 ± 0.4 kDa, respectively (7) (Figure 3A). Phosphorylation of GSK-3 was examined 
using a phospho-GSK-3α and -β-specific antibody. There was no change with ageing in the levels of 
total GSK-3α and -β nor did the ratio of phospho-GSK-3α:GSK-3α differ with age. However, the 
phospho-GSK-3β:GSK-3β ratio increased significantly in old brains compared to young and middle-
aged subjects (p< 0.05, Figure 3A,B).  
Levels of CME-related proteins are upregulated with ageing  
Since Aβ levels have been linked to endocytosis, the expression of proteins involved in CME was 
examined to identify whether there were alterations with ageing. The expression of CHC was 
significantly increased with ageing; increasing by 1.7 and 2.8 times in middle-aged and old groups, 
respectively, in relation to the young group (p< 0.05, Figure 4A). Dynamin-1 was also affected by 
ageing as its level was approximately 3.6 times higher in old subjects compared to young subjects 
(p< 0.05, Figure 4B), while the level in middle-aged samples was not significantly different to the 
other ages. In contrast, dynamin-2 expression did not differ with ageing (Supplementary Figure 
1A,B). 
Three bands were detected for PICALM with molecular masses of 71.1 ± 0.1 kDa, 66.8 ± 0.4 kDa 
and 61 ± 0.4 kDa (Figure 4C). Four main isoforms of PICALM have been identified in man (NCBI 
Reference Sequence Database, RefSeq) NP_009097.2, NP_001008660.1, NP_001193875.1, and 
NP_001193876.1). It is likely that the 71.1 kDa band equates to isoform 1 with a predicted mass of 
70.6 kDa, the 66.8 kDa band to isoform 2 with a predicted mass of 66.3 kDa and the 61 kDa band to 
isoform 4 with a predicted mass of 59.8 kDa (Figure 4C). Isoform 3 with a predicted mass of 69.9 
kDa, was not well resolved from isoform 1 due to their similar masses, so they were analysed together. 
While PICALM isoforms 1 and 2 were not altered with ageing, the level of PICALM isoform 4 was 
about 2.3 times higher in middle-aged subjects in comparison to young cases (p< 0.05, Figure 4C,D) 
with no significant change seen in old subjects. 
AP180, a PICALM homologue (12), exists in multiple isoforms (NCBI Reference Sequence 
Database, RefSeq) with molecular masses ranging from 78.6 to 92.4 kDa. Here AP180 was detected 
as multiple bands ranging from 83.7 to 145.5 kDa (Figure 4E). Levels of AP180 increased 
significantly with ageing being 1.5 times higher in old subjects compared to middle-aged cases (p< 
0.05, Figure 4E) while levels in young subjects were not significantly different to the other groups. 
Since AP-2 appears essential and specific for the early stages of endocytosis (12), its expression was 
also examined but no change was seen with age (Supplementary Figure 1A,B). 
There are at least 15 different isoforms of BIN1, most of which are expressed in the brain including 
the largest, isoform 1, believed to be expressed exclusively in neurons (34). Here BIN-1 was detected 
as three separate bands; the largest band at 77.4 ± 56.1 kDa is likely to equate to isoform 1, while the 
other bands at 64.2 ± 0.5 kDa and 56.1 ± 0.4 kDa equate to two of the smaller isoforms (53). None 
of the BIN-1 isoforms were changed with age (Supplementary Figure 1A,B). 
The expression of Rab5, an early endosome marker (21) was significantly increased in old and 
middle-aged groups by approximately 1.9 and 1.8 times, respectively, in comparison to the young 
subjects (p< 0.05, Figure 4F). SorLA levels, however, did not vary with ageing (Supplementary 
Figure 1A,B).  
Levels of some CIE-related proteins are altered with ageing  
We then examined how the level of proteins involved in CIE change with age. While caveolin-1 
remained constant with age (Figure 5A), caveolin-2 was significantly elevated in old subjects by 
approximately 1.9 and 1.8 times in comparison to middle-aged and young cases, respectively (p<0.05, 
Figure 5B). Conversely, caveolin-3 was significantly decreased with ageing; 2.6 times lower in old 
subjects in comparison to young cases (p< 0.05, Figure 5C). The expression of flotillin-1 was not 
significantly altered with age (Figure 5D). In contrast, the level of flotillin-2 was 2.3 times higher in 
older subjects compared to young cases (p< 0.05, Figure 5E). 
APOE genotypes do not correlate with any parameter 
APOE genotypes were investigated to determine whether there was any correlation between genotype 
and the levels of APP metabolites or endocytic protein expression. We found that 46% of the cases 
carried APOE e3/3, 34.5% carried e3/4, 8% carried e2/4 and 11.5% carried e2/3 alleles. In total 11 
(42%) participants carried the APOE e4 allele, but there was no significant relationship between 
carriers of the APOE e4 allele collapsed across all ages and any parameter examined in the current 
study. 
 
Discussion 
This study demonstrates for the first time an age-related increase in the levels of a number of 
endocytic proteins involved in CME in non-diseased male human brains. Proteins involved in CIE 
were also increased with age. Combined with these findings, there was an age-linked increase in the 
absolute levels of A40 and A42 as well as an increase in the ratio of Aβ42 to Aβ40. In contrast, 
levels of APP, its metabolites and the relevant secretases were unchanged with age. The expression 
of total tau and p-GSK-3α was not affected by ageing, but levels of p-GSK-3β were elevated in old 
brains. 
We obtained our brain samples from the Sudden Death Edinburgh Brain and Tissue Bank and the 
Newcastle Brain Tissue Resource which collect brain samples from individuals dying for a variety of 
reasons. We know that these individuals did not have a known history of dementia before death, did 
not present with any neuropathological symptoms of AD after death and died from a number of causes 
unrelated to AD. Thus we have considered these samples to come from non-diseased subjects 
representative of normal ageing. We compared human brain samples representing periods in life 
before the start of any signs of future AD pathology such as the accumulation of A (20-30 years), 
potentially during the early pre-clinical stages of disease initiation (45-55 years) and at the time when 
clinical symptoms of AD pathology often manifest (70-90 years). Thus our study allows us to draw 
conclusions about factors affected by ageing which could predispose a person to develop AD. In 
addition to a broad age range, we also used brains only from men to control for the effects of gender 
on any age-related changes we saw. There were no significant differences in post-mortem delay or 
brain pH between our age groups (data not shown) thus making it highly unlikely that our data can 
be explained by either of these factors. 
The expression of different APOE alleles is associated with differential risk of developing AD. APOE 
e4 is associated with increased prevalence of AD and lower age of onset (35). In contrast, e2 alleles 
are protective against the development of AD (55). The distribution of the APOE alleles here agrees 
with previous studies (36). We did not see any correlation between expression of the e4 allele and 
any of the proteins we examined suggesting that APOE genotype does not affect the expression of 
endocytic proteins. However, as only 11 of our cases across all ages expressed the e4 allele, it is 
possible that we lacked the power to detect any correlations. 
Previously, ageing has been associated with increased A load in human brain samples (37). These 
observations were replicated here where the levels of soluble and insoluble Aβ40 and Aβ42 were 
significantly higher in brains of old individuals in relation to all younger subjects. We saw a wide 
range of Aβ expression which we believe is representative of the natural variation in Aβ40 and Aβ42 
levels in individuals as there was no correlation between the levels of Aβ40 or Aβ42 with age. This 
was consistent with another study showing that the levels of Aβ increased in parallel with increasing 
age in both humans and APP transgenic mice (38). The level of insoluble Aβ42 was approximately 
double that of Aβ40, consistent with earlier studies indicating that Aβ42 is more prone to form 
aggregates than Aβ40, and hence Aβ42 is considered as an initial and major component of senile 
plaque deposits (6). Interestingly, we did not find any correlations between the levels of soluble and 
insoluble Aβ40 and Aβ42 and the endocytic proteins we examined suggesting that the changes in 
endocytic proteins we see are the cause of amyloid accumulation rather than a consequence. An 
increase in the Aβ42/Aβ40 ratio is a useful diagnostic marker for early-onset familial AD in the brain, 
since the age of onset of familial AD was correlated inversely with the Aβ42/Aβ40 ratio and the level 
of Aβ42 but directly with Aβ40 levels (39). In AD patients the Aβ42/Aβ40 ratio is often shifted to a 
higher percentage of Aβ42 and associated with high synapto-toxicity in brains (40). Since similar 
changes were identified in normal ageing here, our findings indicate a higher likelihood, as expected, 
for older subjects to develop AD.  
Although levels of Aβ increased with age, we saw no corresponding changes in the levels of APP in 
agreement with other studies (37). Interestingly, the other major APP metabolites, βCTF, sAPPα and 
sAPPβ, were also unchanged with age. This was surprising given the increases seen in A40 and 
A42. However, importantly, the level of βCTF was positively correlated with Aβ, particularly with 
insoluble Aβ42 in old brains, indicating that the level of βCTF is indeed associated with those of Aβ. 
Accumulation of βCTF can occur early in the pathogenesis of AD and may induce toxicity resulting 
in synaptic loss and cell death, hence contributing to AD pathology (41). βCTF is also very likely to 
be involved in the development of the enlarged endosomes seen in both AD and Down Syndrome 
(41) via activation of Rab5 leading eventually to endosomal enlargement and accelerated endocytosis 
(41). Since the levels of A40 and A42 increased in old subjects, the proportion of APP undergoing 
beta cleavage may be altered with age but absolute changes in βCTF were too small to detect. The 
levels of sAPPα and sAPPβ were not correlated with either Aβ or βCTF. However, there was a strong 
positive correlation between sAPPα and sAPPβ in young subjects which disappeared in middle-aged 
and old subjects. These data suggest that the control of APP metabolism is tightly regulated earlier in 
life with coordinated activity of - and –secretases but this co-ordination is lost as we age, one 
possible cause of the increase in A seen with ageing. 
Our data suggest that the changes in APP metabolites with age were not due to alterations in 
expression of the secretases responsible for APP metabolism. Levels of ADAM10, one of the most 
important α-secretases and reported to be involved in the molecular pathogenesis of AD (5), were 
unaltered with age implying that the increase in Aβ in old brains was not due to a decrease in α-
secretase activity. This agrees with the unchanged levels of sAPPα. BACE1 mediates –secretase 
cleavage of APP but again its expression did not differ significantly with age, possibly suggesting 
that its activity may not be altered with ageing. In previous reports, although the level of BACE1 was 
constant with age in human brain cortices, its activity was significantly increased with ageing (37), 
indicating a potential role of BACE1 in the production of Aβ in older brains. The positive correlation 
of βCTF and Aβ levels suggests that BACE1 activity is also increased here. PS-1, one of the catalytic 
subunits of γ-secretase (3), was investigated as a marker of γ-secretase. Its expression did not differ 
with age suggesting that the high level of Aβ in older subjects is not due to an increase in γ-secretase 
activity. Our data agree with an earlier study showing that the level of PS-1 and PS-2 mRNA was 
highest in embryonic brains and then declined to remain constant with increasing age (37). 
As abnormal hyper-phosphorylation of tau is important in AD (2), we looked for phosphorylated tau 
in our brain samples but it was undetectable despite using a well-characterised anti-phosphorylated 
tau antibody (31) at a relatively high dilution (1:100). These findings suggest a very low level of this 
protein in non-diseased human brains. In contrast, the levels of Aβ were dramatically higher in the 
old group in relation to the other group consistent with the amyloid cascade hypothesis where Aβ 
deposition develops prior to tau tangle pathology (27). Thus, since none of our subjects were known 
to have AD ante-mortem, it is unlikely that they would have developed NFTs.  
GSK-3 plays a central role in the pathogenesis of AD (42) since it can phosphorylate tau at multiple 
sites (7). It exists as two isoforms, GSK-3α and GSK-3β, which have functional differences (42) and 
the majority of AD-related studies have focussed on the role of GSK-3β (7,). Interestingly, we 
observed a significant increase in the level of active phosphorylated GSK-3β at Tyr279/216 (7) in old 
brains in relation to the other ages, whereas GSK-3α levels were not altered with ageing, supporting 
the functional differences between these two isoforms. This finding indicates that, although there was 
no phosphorylated tau in the old brains, the increase in active GSK-3β could be a precursor for the 
development of NFT along with other events.  
Since the elevation in the level of Aβ in old subjects was not associated with any changes in APP or 
the secretase enzymes, we hypothesised that this increase could be attributed to alterations in 
endocytosis with age, as APP is internalised from the cell surface into endosomes prior to Aβ 
generation (4). Increased APP internalisation would thus result in a rise in Aβ production as the 
substrate would come into contact more with the enzymes.  
Our data clearly show that it is indeed highly likely that CME is increased with ageing. Firstly, and 
most crucially, the level of clathrin was significantly increased with age. Further support for our 
hypothesis was provided by our data on dynamin. Clathrin-coated vesicle budding depends on 
dynamin (12) and neurones express three closely related dynamin proteins (43). Dynamin-2 is 
ubiquitously expressed across tissues, while dynamin-1 and dynamin-3 are selectively enriched in the 
brain, with dynamin-1 more predominant than dynamin-3 (43). We found that, while dynamin-2 was 
unaffected by age, the level of dynamin-1 was significantly higher in old brains. Clathrin relies on 
adaptor proteins and complexes (AP-2) and accessory proteins (AP180) for it to be recruited to the 
plasma membrane (12). We observed a significant increase in the level of AP180 in old brains adding 
extra support to the possibility of increased CME with ageing. Interestingly, the level of AP180 was 
reported to be decreased in several regions of AD brains (44), thus AP180 expression may be 
differentially affected by disease status. Our findings for PICALM, a highly homologous protein, are 
also supportive of an increase in endocytosis with ageing. PICALM aids in the formation of clathrin-
coated pits (45) and is involved in the fusion of clathrin-coated vesicles with endosomes and 
subsequent trafficking (45). It has been linked to AD pathogenesis as discussed above (29) and 
supported by evidence showing that PICALM immunoreactivity was significantly higher in brains 
from AD cases compared to controls (19). We found that the levels of PICALM isoforms 1 and 2 
were not altered with age, whereas PICALM isoform 4 was significantly increased in middle-aged 
brains suggesting it may contribute to the initial rise seen in A in pre-clinical AD (27). The level of 
PICALM may increase in middle-aged brains prior to that of clathrin as PICALM has a crucial role 
in CME (45). PICALM was found to be abnormally cleaved with a band at 50 kDa in AD samples 
(19) but we only detected full-length PICALM in our brain samples. Our final evidence for an 
increase in CME with ageing comes from Rab5. Rab5 is an essential effector molecule which 
facilitates early endosome fusion and targets endosomes to the lysosomes (21). The association of 
increased Rab5 expression with AD was described 20 years ago (21-22). We saw significantly 
increased Rab5 levels in both middle-aged and older brains suggesting that endocytic uptake is 
elevated. Interestingly, the increase in Rab5 in the middle-aged brains occurred prior to the elevations 
observed for Aβ and the other CME proteins except PICALM agreeing with previous findings 
showing that Rab5-positive endosome enlargement is a pathological feature preceding A deposition 
and subsequent pathological changes (22). Thus, we believe that an increase in Rab5 levels may be 
involved in the initiation of changes in endocytosis which could contribute to increased Aβ levels and 
the subsequent development of AD. 
Interestingly, not all proteins associated with CME were affected by ageing. BIN-1 is a major binding 
partner of dynamin (12) and is linked to AD as discussed above. Further, the level of BIN-1 was 
found to be altered in AD but was not correlated with those of Aβ or phosphorylated tau (46). We 
detected BIN-1 as multiple isoforms with no changes in any of the isoforms seen with age, suggesting 
that the activity of BIN-1 was unaffected by age. Likewise, no correlation was observed between the 
level of BIN-1 and age in human brain samples of various ages (46). However, the lack of effect of 
ageing on BIN-1 could be due to the complexity of the many isoforms of this protein with subtle 
changes in isoforms being very difficult to detect. Furthermore, the expression of AP-2 was not 
altered with age although a recent study showed that AP-2 in addition to clathrin is involved in APP 
internalisation and trafficking in mouse hippocampal tissue (47). There are multiple adaptor proteins 
involved in CME (12) which could explain the lack of effect seen for AP2.  
CIE has been also implicated in AD, particularly via caveolins and flotillins (10, 49). Our data indicate 
that CIE may also be increased by ageing although to a lesser extent than CME. Several studies 
demonstrated that caveolins are important for APP processing in the brain. The three isoforms of 
caveolin are all found in the nervous system of mammals (49). APP was enriched in caveolae, and 
caveolin-1 was shown to be physically associated with APP (50). α-Secretase cleavage was also 
described in caveolae and over-expression of caveolin-1 was associated with α-secretase-mediated 
proteolysis of APP (49-50). Here the expression of caveolin-1 was not altered with ageing agreeing 
with a previous report showing no difference in levels in human frontal cortex between AD brains 
and controls (51). Caveolin-2 forms a stable hetero-oligomeric complex with caveolin-1 (51). 
Surprisingly, given the lack of change in caveolin-1, we found that the level of caveolin-2 
significantly increased with ageing suggesting a possible increase in the process of endocytosis via 
caveolae and thus an increase in APP endocytosis. Caveolin-3 is also a principal component of 
caveolae (49). Caveolin-3 interacts and colocalises with APP and its immuno-reactivity increased in 
astroglial cells surrounding senile plaques in AD brains (52). In contrast to caveolin-1 and -2, we 
observed a significant fall in caveolin-3 in older brains. As caveolin-3 is predominantly expressed in 
brain astroglial cells (49), it is possible there may be decreased caveolin-mediated endocytosis in 
these cells or fewer of these cells, and thus less APP may be internalised.  
Flotillin is also associated with cholesterol-rich membranes involved in the generation of Aβ (53). 
Accumulation of flotillin-1 was observed in the endosomes of neurons from AD patients (53). We 
found that the level of flotillin-2 was significantly higher in old brains while flotillin-1 was unaffected 
by ageing. The effect of ageing on flotillin-2 is relevant as it is involved in the endocytosis of APP 
while flotillin-1 is not (54) and flotillin-2-dependent clustering of APP has been found to initiate its 
internalisation into the CME pathway (54). Thus, the increase in flotillin-2 observed in old brains 
may trigger greater internalisation of APP and its subsequent metabolism to Aβ which could partially 
account for the higher level of Aβ detected in old brains.  
In conclusion, we have demonstrated for the first time clear evidence that the levels of several proteins 
involved in CME and CIE are increased with age in the human brains. Increased levels of these 
proteins in old brains suggest an age-related up-regulation in the process of endocytosis which would 
affect many proteins including APP. This could explain the elevation seen in the level of Aβ in the 
old brains. Critically, the increase in Rab5 occurred earlier in life compared to the increase in Aβ. 
Rab5 has been implicated in protein transport from the plasma membrane to early endosomes during 
CME in a variety of cells. We therefore propose that there is an age-related increase in endocytosis 
activity starting with Rab5 and followed later in life by increases in various CME and CIE proteins. 
This increase in endocytosis, when combined with other factors, could predispose older individuals 
to develop AD by increasing the internalisation of APP and thus its subsequent metabolism to 
generate Aβ. Therefore these novel findings could explain in part why ageing is the most important 
risk factor for AD. 
 
Conflicts of interest 
None of the authors have any conflicts of interest. 
 
Funding 
This work and MA were supported by Bristol Research into Alzheimer's and Care of Elderly 
(BRACE). 
 
 
 
Acknowledgments 
The authors gratefully acknowledge Dr Mina Ryten and Prof. John Hardy for providing some of the 
APOE genotyping data and Rhodri Thomas and Prof Julie Williams for their help with APOE 
genotyping. The authors thank Prof. Peter Davies for generously providing the PHF-1 antibody. The 
authors gratefully acknowledge the Sudden Death Edinburgh Brain and Tissue Bank (funded by the 
Medical Research Council) for generously providing the human brain samples. Brain samples for this 
study were also provided by the Newcastle Brain Tissue Resource which is funded in part by a grant 
from the UK Medical Research Council (G0400074), by NIHR Newcastle Biomedical Research 
Centre and Unit awarded to the Newcastle upon Tyne NHS Foundation Trust and Newcastle 
University, and by a grant from Alzheimer's Society and Alzheimer's Research Trust as part of the 
Brains for Dementia Research Project. 
 
 
 
 
 
 
 
 
 
 
References 
1. Alzheimer’s Association. 2016 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 
2016;12:459-509. 
2. Citron M. Strategies for disease modification in Alzheimer's disease. Nature Reviews 
Neuroscience. 2004;5:677-685. 
3. Wolfe MS. Inhibition and modulation of γ-secretase for Alzheimer's disease. Neurotherapeutics. 
2008;5:391-398. 
4. Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the 
endocytic pathway. Journal of Biological Chemistry. 1994;269:17386-17389. 
5. Saftig P, Lichtenthaler SF. The alpha secretase ADAM10: A metalloprotease with multiple 
functions in the brain. Progress in Neurobiology. 2015;135:1-20. 
6. Welander H, Frånberg J, Graff C, Sundström E, Winblad B, Tjernberg LO. Aβ43 is more frequent 
than Aβ40 in amyloid plaque cores from Alzheimer disease brains. Journal of Neurochemistry. 
2009;110:697-706. 
7. Jiang J, Wang Z-H, Qu M, Gao D, Liu X-P, Zhu L-Q, et al. Stimulation of EphB2 attenuates tau 
phosphorylation through PI3K/Akt-mediated inactivation of glycogen synthase kinase-3β. Scientific 
Reports. 2015;5. 
8. Tate BA, Mathews PM. Targeting the role of the endosome in the pathophysiology of 
Alzheimer's disease: a strategy for treatment. Science's SAGE KE. 2006;2006:re2. 
9. Bitsikas V, Correa IR, Jr., Nichols BJ. Clathrin-independent pathways do not contribute 
significantly to endocytic flux. eLife. 2014;3:e03970. 
10. Gaudreault SB, Dea D, Poirier J. Increased caveolin-1 expression in Alzheimer’s disease brain. 
Neurobiology of Aging. 2004;25:753-759. 
11. Okamoto CT. Endocytosis and transcytosis. Advanced Drug Delivery Reviews. 1998;29:215-
228. 
12. McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-
mediated endocytosis. Nature Reviews Molecular Cell Biology. 2011;12:517-533. 
13. Harder T, Simons K. Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol 
microdomains. Current Opinion in Cell Biology. 1997;9:534-542. 
14. Fra AM, Williamson E, Simons K, Parton RG. De novo formation of caveolae in lymphocytes 
by expression of VIP21-caveolin. Proceedings of the National Academy of Sciences. 1995;92:8655-
8659. 
15. Parton RG, Howes MT. Revisiting caveolin trafficking: the end of the caveosome. Journal of 
Cell Biology. 2010;191:439-441. 
16. Nakadate K. Developmental changes in the flotillin-1 expression pattern of the rat visual cortex. 
Neuroscience. 2015;292:101-111. 
17. Santiago JM, Torrado AI, Arocho LC, Rosas OR, Rodríguez AE, Toro FK, et al. Expression 
profile of flotillin-2 and its pathophysiological role after spinal cord injury. Journal of Molecular 
Neuroscience. 2013;49:347-359. 
18. Cordy JM, Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer's 
disease (Review). Molecular Membrane Biology. 2006;23:111-122. 
19. Ando K, Brion J-P, Stygelbout V, Suain V, Authelet M, Dedecker R, et al. Clathrin adaptor 
CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer’s brains. Acta 
Neuropathologica. 2013;125:861-878. 
20. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis 
of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics. 
2013;45:1452-1458. 
21. Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased neuronal endocytosis and protease 
delivery to early endosomes in sporadic Alzheimer’s disease: neuropathologic evidence for a 
mechanism of increased β-amyloidogenesis. Journal of Neuroscience. 1997;17:6142-6151. 
22. Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. Endocytic 
pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down 
syndrome: differential effects of APOE genotype and presenilin mutations. American Journal of 
Pathology. 2000;157:277-286. 
23. Thomas RS, Lelos MJ, Good MA, Kidd EJ. Clathrin-mediated endocytic proteins are upregulated 
in the cortex of the Tg2576 mouse model of Alzheimer’s disease-like amyloid pathology. 
Biochemical and Biophysical Research Communications. 2011;415:656-661. 
24. Cirrito JR, Kang J-E, Lee J, Stewart FR, Verges DK, Silverio LM, et al. Endocytosis is required 
for synaptic activity-dependent release of amyloid-β in vivo. Neuron. 2008;58:42-51. 
25. Thakurta IG, Andersen O. Associations of sorLA/SORL1 with Alzheimer's disease. Receptors 
& Clinical Investigation. 2015;2. 
26. Jorm A, Korten A, Henderson A. The prevalence of dementia: a quantitative integration of the 
literature. Acta Psychiatrica Scandinavica. 1987;76:465-479. 
27. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of 
Alzheimer's disease. Nature. 2009;461:916-922. 
28. Rees T, Hammond P, Soreq H, Younkin S, Brimijoin S. Acetylcholinesterase promotes beta-
amyloid plaques in cerebral cortex. Neurobiology of Aging. 2003;24:777-787. 
29. Thomas RS, Henson A, Gerrish A, Jones L, Williams J, Kidd EJ. Decreasing the expression of 
PICALM reduces endocytosis and the activity of beta-secretase: implications for Alzheimer's disease. 
BMC Neuroscience. 2016;17:50. 
30. Thomas RS, Liddell JE, Kidd EJ. Anti‐amyloid precursor protein immunoglobulins inhibit 
amyloid‐β production by steric hindrance. FEBS Journal. 2011;278:167-178. 
31. Ide M, Harris M, Stevens A, Sussams R, Hopkins V, Culliford D, et al. Periodontitis and 
Cognitive Decline in Alzheimer's Disease. PloS One. 2016;11:e0151081. 
32. Yan R, Han P, Miao H, Greengard P, Xu H. The transmembrane domain of the Alzheimer's beta-
secretase (BACE1) determines its late Golgi localization and access to beta -amyloid precursor 
protein (APP) substrate. Journal of Biological Chemistry. 2001;276:36788-36796. 
33. Petry FR, Pelletier J, Bretteville A, Morin F, Calon F, Hébert SS, et al. Specificity of anti-tau 
antibodies when analyzing mice models of Alzheimer's disease: problems and solutions. PloS One. 
2014;9:e94251. 
34. Holler CJ, Davis PR, Beckett TL, Platt TL, Webb RL, Head E, et al. Bridging Integrator 1 (BIN1) 
Protein Expression Increases in the Alzheimer’s Disease Brain and Correlates with Neurofibrillary 
Tangle Pathology. Journal of Alzheimer's disease: JAD. 2014;42:1221. 
35. Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms 
and therapy. Nature Reviews Neurology. 2013;9:106-118. 
36. Ewbank DC. The APOE Gene and Differences in Life Expectancy in Europe. Journals of 
Gerontology Series A: Biological Sciences and Medical Sciences. 2004;59:B16-B20. 
37. Fukumoto H, Rosene DL, Moss MB, Raju S, Hyman BT, Irizarry MC. β-secretase activity 
increases with aging in human, monkey, and mouse brain. American Journal of Pathology. 
2004;164:719-725. 
38. Fukumoto H, Asami-Odaka A, Suzuki N, Shimada H, Ihara Y, Iwatsubo T. Amyloid beta protein 
deposition in normal aging has the same characteristics as that in Alzheimer's disease. Predominance 
of A beta 42 (43) and association of A beta 40 with cored plaques. American Journal of Pathology. 
1996;148:259. 
39. Kumar‐Singh S, Theuns J, Van Broeck B, Pirici D, Vennekens Kl, Corsmit E, et al. Mean age‐
of‐onset of familial alzheimer disease caused by presenilin mutations correlates with both increased 
Aβ42 and decreased Aβ40. Human Mutation. 2006;27:686-695. 
40. Pauwels K, Williams TL, Morris KL, Jonckheere W, Vandersteen A, Kelly G, et al. Structural 
basis for increased toxicity of pathological aβ42: aβ40 ratios in Alzheimer disease. Journal of 
Biological Chemistry. 2012;287:5650-5660. 
41. Kim S, Sato Y, Mohan PS, Peterhoff C, Pensalfini A, Rigoglioso A, et al. Evidence that the rab5 
effector APPL1 mediates APP-[beta]CTF-induced dysfunction of endosomes in Down syndrome and 
Alzheimer/'s disease. Molecular Psychiatry. 2016; 21:707–716. 
42. Hooper C, Killick R, Lovestone S. The GSK3 hypothesis of Alzheimer’s disease. Journal of 
Neurochemistry. 2008;104:1433-1439. 
43. Calabrese B, Halpain S. Differential targeting of dynamin-1 and dynamin-3 to nerve terminals 
during chronic suppression of neuronal activity. Molecular and Cellular Neuroscience. 2015;68:36-
45. 
44. Yao P, Morsch R, Callahan L, Coleman P. Changes in synaptic expression of clathrin assembly 
protein AP180 in Alzheimer's disease analysed by immunohistochemistry. Neuroscience. 
1999;94:389-394. 
45. Xiao Q, Gil S-C, Yan P, Wang Y, Han S, Gonzales E, et al. Role of phosphatidylinositol clathrin 
assembly lymphoid-myeloid leukemia (PICALM) in intracellular amyloid precursor protein (APP) 
processing and amyloid plaque pathogenesis. Journal of Biological Chemistry. 2012;287:21279-
21289. 
46. Glennon EBC, Whitehouse IJ, Miners JS, Kehoe PG, Love S, Kellett KAB, et al. BIN1 Is 
Decreased in Sporadic but Not Familial Alzheimer’s Disease or in Aging. PloS One. 2013;8:e78806. 
47. Poulsen ET, Larsen A, Zollo A, Jørgensen AL, Sanggaard KW, Enghild JJ, et al. New Insights 
to Clathrin and Adaptor Protein 2 for the Design and Development of Therapeutic Strategies.  
International Journal of Molecular Sciences. 2015;16:29446-29453. 
48. Girardot N, Allinquant B, Duyckaerts C. [Lipid rafts, flotillin-1 and Alzheimer disease]. Journal 
de la Societe de Biologie. 2002;197:223-229. 
49. Ikezu T, Ueda H, Trapp BD, Nishiyama K, Sha JF, Volonte D, et al. Affinity-purification and 
characterization of caveolins from the brain: differential expression of caveolin-1,-2, and-3 in brain 
endothelial and astroglial cell types. Brain Research. 1998;804:177-192. 
50. Ikezu T, Trapp BD, Song KS, Schlegel A, Lisanti MP, Okamoto T. Caveolae, plasma membrane 
microdomains for α-secretase-mediated processing of the amyloid precursor protein. Journal of 
Biological Chemistry. 1998;273:10485-10495. 
51. Van Helmond Z, Miners J, Bednall E, Chalmers K, Zhang Y, Wilcock G, et al. Caveolin‐1 and‐
2 and their relationship to cerebral amyloid angiopathy in Alzheimer's disease. Neuropathology and 
Applied Neurobiology. 2007;33:317-327. 
52. Nishiyama K, Trapp BD, Ikezu T, Ransohoff RM, Tomita T, Iwatsubo T, et al. Caveolin-3 
Upregulation Activates β-Secretase–Mediated Cleavage of the Amyloid Precursor Protein in 
Alzheimer’s Disease. Journal of Neuroscience. 1999;19:6538-6548. 
53. Girardot N, Allinquant B, Langui D, Laquerriere A, Dubois B, Hauw JJ, et al. Accumulation of 
flotillin‐1 in tangle‐bearing neurones of Alzheimer's disease. Neuropathology and Applied 
Neurobiology. 2003;29:451-461. 
54. Schneider A, Rajendran L, Honsho M, Gralle M, Donnert G, Wouters F, et al. Flotillin-dependent 
clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing 
in neurons. Journal of Neuroscience. 2008;28:2874-2882. 
  
Table 1 Summary of the sample identifiers, ages, gender, post-mortem intervals and pH of the 
human frontal cortex brain samples 
 
Brain Bank 
sample 
identifier 
MRCa 
identifier 
Age 
(years) 
Gender 
Post-mortem 
interval (hours) 
pH of 
tissue 
  Young    
SD042/12 BBN_7270 29 M 44 6.5 
SD014/09 BBN_2473 26 M 44 6.3 
SD021/10 BBN_2518 27 M 67 6.2 
SD025/05 BBN_2322 28 M 38 6.6 
SD041/05 BBN_2335 24 M 51 6.3 
SD027/06 BBN_2367 25 M 41 6.5 
SD006/09 BBN_2465 25 M 81 6.4 
SD008/09 BBN_2467 25 M 79 5.9 
SD030/11  BBN_2569 30 M 71 6.4 
SD008/12 BBN_3771 25 M 53 6.4 
  Middle-aged    
SD038/12 BBN_4176 51 M 45 6.4 
SD023/13   BBN_15221 53 M 114 6.1 
SD003/11 BBN_2542 49 M 44 6.2 
SD023/12 BBN_3785 50 M 45 6.3 
SD015/10 BBN_2512 52 M 47 6.2 
SD037/11 BBN_2576 48 M 46 6.2 
SD025/13   BBN_15223 47 M 42 6.5 
SD004/10 BBN_2501 50 M 63 6.2 
SD033/10 BBN_2530 51 M 52 6.3 
SD044/12 BBN_7271 46 M 52 6.6 
  Old    
 SD016/11 BBN_2555 74 M 66 6.3 
SD034/08 BBN_2453 70 M 50 6.2 
SD025/10 BBN_2522 75 M 47 5.4 
SD023/10 BBN_2520 74 M 44 6.4 
SD015/12 BBN_3778 70 M 74 6.9 
SD036/12 BBN_4174 75 M 78 6.4 
SD055/12 BBN_9508 76 M 90 6.8 
20040091 BBN_7386 75 M 64 NDb 
20140411   BBN_24265 88 M 28 6.3 
 
aMRC – Medical Research Council 
bND – not determined 
 
 
 
  
Figures 
 
Figure 1 Comparison of the levels of (A) APP, (B) soluble and insoluble Aβ40, (C) soluble and 
insoluble Aβ42, (D) the soluble and insoluble Aβ42/Aβ40 ratio and (E) βCTF in male human brain 
frontal cortex samples of old (70-90) non-diseased subjects compared to middle-aged (45-55) and 
young (20-30) non-diseased subjects. (A) Levels of APP were not changed with ageing. (B-D) Levels 
of soluble/insoluble Aβ40, soluble/insoluble Aβ42 and the insoluble Aβ42/Aβ40 ratio were 
significantly increased with age in human brains, while the soluble Aβ42/Aβ40 ratio was not 
significantly affected by age. (E) Levels of βCTF did not differ significantly with age. Data are 
represented as mean ± S.E.M. *p< 0.05 non-parametric Kruskal-Wallis test followed by Dunn's post-
hoc test. n=6-10. 
 
  
 Figure 2 Linear regression analysis of insoluble Aβ42 and βCTF levels in the (A) young (20-30) 
group, (B) middle-aged (45-55) group and (C) old (70-90) group; sAPPα and sAPPβ levels in the (D) 
young group, (E) middle-age group and (F) old group. (A-C) Levels of Aβ42 were positively 
correlated with those of βCTF in all age groups. (D) The level of sAPPα was positively correlated 
with that of sAPPβ in the young group, while there was no correlation between sAPPα and sAPPβ 
levels in middle-aged and old groups (E, F). Pearson correlation analysis. n=6-7. 
  
 Figure 3 Comparison of total tau, phospho-GSK-3α:GSK-3α and phospho-GSK-3β:GSK-3β in male 
human brain frontal cortex samples of old (70-90) non-diseased subjects compared to middle-aged 
(45-55) and young (20-30) non-diseased subjects. (A) Representative immunoblots of the proteins in 
brain samples of different ages and (B) densitometric analysis of the immunoblots. Levels of 
phospho-GSK-3β were significantly increased with ageing while levels of phospho-GSK-3α and total 
tau were unchanged with age. Data are represented as mean ± S.E.M. *p< 0.05, one-way ANOVA 
followed by Tukey's post-hoc tests. n=6-7. 
  
 Figure 4 Comparison of CME-related proteins in male human brain frontal cortex samples of old 
(70-90) non-diseased subjects compared to middle-aged (45-55) and young (20-30) non-diseased 
subjects. Each section shows a representative immunoblot of a protein in brain samples of different 
ages and densitometric analysis of the immunoblots: (A) clathrin heavy chain, (B) dynamin-1, (C) 
PICALM isoforms 1 and 2, (D) PICALM isoform 4, (E) AP180 and (F) Rab5. Levels of clathrin, 
dynamin-1, PICALM (isoform 4), AP-180 and Rab-5 were all significantly increased with ageing in 
human brains. Levels of PICALM (isoforms 1 & 2) were not altered with age. Data are represented 
as mean ± S.E.M. *p< 0.05, ***p< 0.001, one-way ANOVA followed by Tukey's post-hoc tests. n=6-
7. 
  
 Figure 5 Comparison of CIE-related proteins in male human brain frontal cortex samples of old (70-
90) non-diseased subjects compared to middle-aged (45-55) and young (20-30) non-diseased 
subjects. Each section shows a representative immunoblot of a protein in brain samples of different 
ages and densitometric analysis of the immunoblots: (A) caveolin-1, (B) caveolin-2, (C) caveolin-3, 
(D) flotillin-1 and (E) flotillin-2. Levels of caveolin-1 and flotillin-1 were unchanged with age, while 
the level of caveolin-3 was significantly decreased with age and caveolin-2 and flotillin-2 levels were 
significantly increased with age. Data are represented as mean ± S.E.M. *p< 0.05, **p< 0.01, one-
way ANOVA followed by Tukey's post-hoc tests. n=6-7. 
  
Supplementary data Figures 
 
Supplementary Figure 1 Comparison of APP, BIN1, AP-2, dynamin-2, sorLA and α-, β- and γ-
secretase enzymes in male human brain frontal cortex samples of old (70-90) non-diseased subjects 
compared to middle-aged (45-55) and young (20-30) non-diseased subjects. (A) Representative 
immunoblots of the proteins in human brain samples of different ages and (B) densitometric 
analysis of the immunoblots. Levels of APP, BIN1, AP-2, dynamin-2, sorLA, mature/immature 
ADAM10 and BACE1 and PS-1 (full length and cleaved derivatives) were not significantly altered 
with age. Data are represented as mean ± S.E.M. n=6-7. 
  
 Supplementary Figure 2 Linear regression analysis of soluble Aβ42 and βCTF levels in the (A) 
young (20-30) group, (B) middle-aged (45-55) group and (C) old (70-90) group; soluble Aβ40 and 
βCTF levels in the (D) young group, (E) middle-aged group and (F) old group; insoluble Aβ40 and 
βCTF levels in the (G) young group, (H) middle-aged group and (I) old group. Comparison of the 
levels of (J) sAPPα and (K) sAPPβ in male human brain frontal cortex samples of old non-diseased 
subjects compared to middle-aged and young non-diseased subjects. No significant differences were 
found between any of these comparisons. n=6-10. 
 
